Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (6): 948-952    DOI: 10.12892/ejgo4700.2019
Original Research Previous articles | Next articles
Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques
N. K. Šuster1, M. Meznaric2, N. Škorja2, I. Virant-Klun3, I. Verdenik4, Š. Smrkolj1, 2, *()
1Department of Gynecology, Division of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana, Slovenia
2Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3Department of human reproduction, Division of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana, Slovenia
4Research Unit, Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Download:  PDF(747KB)  ( 199 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose of Investigation: The objective of the study was to evaluate cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting (WB) and to compare WB results to immunohistochemical (IHC) results of NANOG expression in the same tumors. Materials and Methods: Of the 37 ovarian tumor samples obtained intraoperatively, diagnosis of ovarian serous tumors was established histopathologically in 17 cases. WB and IHC for NANOG was performed on the parallel portions of the same ovarian tumors in the latter cases. The IHC staining samples were made up of a NANOG positive and a NANOG-negative group. Pursuant to summation of signal intensity and positive cell occurrence, the authors additionally divided the NANOG-positive group into three subgroups. Correlation coefficient between NANOG WB and NANOG IHC results was calculated. Results: NANOG measured by means of WB was significantly higher in the IHC determined NANOG-positive group than in the NANOG-negative group (p = 0.003). Comparison of the amount of NANOG measured by WB and IHC scores of individual cases revealed substantial dispersion of WB results among the NANOG subgroups; the dispersion was largest when NANOG was IHC only slightly-positive. In the NANOG moderate- and strongly-positive subgroups, WB values were higher and more homogenously arranged. In all IHC determined NANOG-negative cases NANOG WB values were low, with low value variability among tumor samples. However, correlation between NANOG WB results and NANOG IHC scoring subgroups revealed statistical significance (r = 0.73, p = 0.001). Conclusion: By means of WB and IHC the authors demonstrated NANOG to be a potential marker of ovarian high-grade serous carcinoma. Further research on the correlation between NANOG WB expression and clinical parameters is needed.

Key words:  Ovarian cancer      Cancer stem cell-related marker      NANOG      Western blotting      Immunohistochemistry     
Published:  10 December 2019     
*Corresponding Author(s):  Š. SMRKOLJ     E-mail:  spsmrkolj@gmail.com

Cite this article: 

N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4700.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I6/948

[1] Jaudah Al-Maghrabi, Haneen Al-Maghrabi. SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 699-704.
[2] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[3] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[4] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[5] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[6] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[7] Hyang Sook Jeong, Yuki Gen, Hui Ryun Joo, Ji Geun Yoo, Seung Geun Yeo, Dong Choon Park. Mesonephric-like carcinoma of the uterine corpus: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 664-667.
[8] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[9] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[10] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[11] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[12] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[13] Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.
[14] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[15] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
No Suggested Reading articles found!